---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-042017"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:09:30.328354+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics Q1 2025 net loss $21.2M; cash $48.8M; briquilimab programs on track

## Summary
- Net loss of $21.2M ($1.41 per share) for Q1 2025; R&D expenses $16.2M, G&A $5.6M.
- Cash and equivalents totaled $48.8M as of March 31, 2025.
- BEACON CSU study data (including OLE) expected first half of Q3 2025; Phase 2b planned for H2 2025.
- SPOTLIGHT CIndU study full cohort enrolled; additional data at EAACI June 2025.
- ETESIAN asthma allergen challenge study enrolling; initial data expected H2 2025.

## SEC filing metadata
- accession: 0001213900-25-042017
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390025042017/0001213900-25-042017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390025042017/ea0241732-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-042017
- JSON: https://secwatch.observer/filing/0001213900-25-042017.json
- Plain text: https://secwatch.observer/filing/0001213900-25-042017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.